Cargando…
Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink
BACKGROUND: Intensification of metformin monotherapy with additional glucose-lowering drugs is often required in patients with type 2 diabetes (T2D). This study evaluated changes in HbA1c and weight, as well as treatment persistence, associated with different second-line therapies used in UK clinica...
Autores principales: | Wilding, John, Godec, Thomas, Khunti, Kamlesh, Pocock, Stuart, Fox, Robin, Smeeth, Liam, Clauson, Per, Fenici, Peter, Hammar, Niklas, Medina, Jesús |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047134/ https://www.ncbi.nlm.nih.gov/pubmed/30008267 http://dx.doi.org/10.1186/s12916-018-1085-8 |
Ejemplares similares
-
Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany
por: Khunti, Kamlesh, et al.
Publicado: (2017) -
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
por: Khunti, Kamlesh, et al.
Publicado: (2017) -
Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study
por: Gomes, Marília B., et al.
Publicado: (2022) -
Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2019) -
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)